EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis

Hui Yu Juan, Shwu-Jiuan Sheu, De-Kuang Hwang iD

Journal of Ocular Pharmacology and Therapeutics · 01.03.2025 · 41 (2) · 44-53

DOI: 10.1089/jop.2024.0100 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Ocular Pharmacology and Therapeutics, online erschienen am 05.03.2025. Verfasst von Hui Yu Juan und 2 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors, Uveitis, Janus Kinases. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 101 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Uveitis remains one of the leading causes of blindness worldwide, with different etiologies requiring separate approaches to treatment. For over a decade, oral, topical, and local injection of corticosteroids as well as systemic conventional disease-modifying antirheumatic drugs (DMARDs) have remained the most effective treatment for noninfectious uveitis (NIU). Systemic administration of antitumor necrosis factor-α and other biological DMARDs have been used for treating cases that responded inadequately to conventional treatments. Unfortunately, some refractory patients still suffer from frequent attacks despite the combination of multiple treatments. Recently, there has been promising evidence for Janus kinase (JAK) inhibitors as the next-generation therapy for NIU. The JAK/signal transducers and activators of the transcription (STAT) signaling pathway mediate the downstream events involved in immune fitness, tissue repair, inflammation, apoptosis, and adipogenesis by binding various ligands, such as cytokines, growth hormones, and growth factors. The mutation or loss of JAK/STAT components is implicated in autoimmune diseases, thus inhibition of such pathways has been an important area of research in therapeutic development. 1 In this review, we provide a comprehensive overview of the efficacy and safety of JAK inhibitors for the management of NIU, with evidence from current trials and case reports.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsUveitisJanus KinasesHumansAnimalsSignal Transduction

Stichwörter der Autor:innen

JAKJanus kinase inhibitorsnoninfectious uveitistherapytyrosine kinase

Substanzen

Janus Kinase InhibitorsJanus Kinases

Autor:innen und Institutionen

  • Virginia Commonwealth University School of Medicine, Richmond, Virginia, USA.
  • Department of Ophthalmology, School of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
  • Department of Ophthalmology, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
  • Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Ophthalmology, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.

ORCID-Profile: De-Kuang Hwang

Zitieren

APA

Juan, H. Y., Sheu, S. J., & Hwang, D. K. (2025). Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics, 41(2), 44-53. https://doi.org/10.1089/jop.2024.0100

Vancouver

Juan HY, Sheu SJ, Hwang DK. Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis. Journal of Ocular Pharmacology and Therapeutics. 2025;41(2):44-53. doi:10.1089/jop.2024.0100

BibTeX
@article{Juan2025,
  author = {Juan, Hui Yu and Sheu, Shwu-Jiuan and Hwang, De-Kuang},
  title = {Review of Janus Kinase Inhibitors as Therapies for Noninfectious Uveitis},
  journal = {Journal of Ocular Pharmacology and Therapeutics},
  year = {2025},
  volume = {41},
  number = {2},
  pages = {44--53},
  doi = {10.1089/jop.2024.0100}
}
Kostenlos starten →